CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and empathetically with patients navigating a chronic ...

A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter ...

Interim phase 1b data showed 100% partial response rate in efficacy-evaluable CLL/SLL (4/4) after a median of at least three prior treatment lines. In heavily pretreated MZL (n=5), three complete ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.

Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in ...

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

Baystreet.ca News Commentary — The global oncology and cancer drugs market, valued at $167 billion in 2023, is projected to reach $335.2 billion by 2033 at a compound annual growth ...

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...